Thermodynamically optimal information gain in finite-time measurement
Physical Review Research · 03.09.2024 · 6 (3)
DOI: 10.1103/physrevresearch.6.033239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physical Review Research, online erschienen am 03.09.2024. Verfasst von Rihito Nagase und 1 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Tokyo, Japan Society for the Promotion of Science, Japan Science and Technology Corporation.
Abstract (Originalsprache)
The tradeoff relation between speed and cost is a central issue in designing fast and efficient information processing devices. We derive an achievable bound on thermodynamic cost for obtaining information through finite-time (non-quasi-static) measurements. Our proof is based on optimal transport theory, which enables us to identify the explicit protocol to achieve the obtained bound. Moreover, we demonstrate that the optimal protocol can be approximately implemented by an experimentally feasible setup with quantum dots. Our results would lead to design principles of high-speed and low-energy-cost information processing. Published by the American Physical Society 2024
Förderung
- University of Tokyo
- Japan Society for the Promotion of Science
- Japan Science and Technology Corporation
Zitieren
APA
Nagase, R., & Sagawa, T. (2024). Thermodynamically optimal information gain in finite-time measurement. Physical Review Research, 6(3). https://doi.org/10.1103/physrevresearch.6.033239
Vancouver
Nagase R, Sagawa T. Thermodynamically optimal information gain in finite-time measurement. Physical Review Research. 2024;6(3). doi:10.1103/physrevresearch.6.033239
BibTeX
@article{Nagase2024,
author = {Nagase, Rihito and Sagawa, Takahiro},
title = {Thermodynamically optimal information gain in finite-time measurement},
journal = {Physical Review Research},
year = {2024},
volume = {6},
number = {3},
doi = {10.1103/physrevresearch.6.033239}
}
EUVIMED